These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 29024304)

  • 21. Increased urinary adiponectin level is associated with contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention.
    Zhang JY; Wang Q; Wang RT; Li F; Cheng HX; Lian K; Liu Y; Tao L
    BMC Cardiovasc Disord; 2019 Jul; 19(1):160. PubMed ID: 31269899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective Effects of Salvianolate on Contrast-Induced Nephropathy after Primary Percutaneous Coronary Intervention: A Prospective Multicenter Randomized Controlled Trial.
    Huang J; Yuan M; Ma J; Liu R; Dong Z; Zhao G; Hang J; Wei J; Ma S; Wei M; Jiang J; Song H; Liu Z; Zhang W; Li J; Lu Z
    Cardiology; 2017; 138(3):169-178. PubMed ID: 28746934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of contrast media on kidney function in patients with stable coronary artery disease.
    Reuter SB; Harutyunyan M; Mygind ND; Jørgensen E; Kastrup J
    Scand Cardiovasc J; 2014 Aug; 48(4):234-40. PubMed ID: 24941300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.
    Capodanno D; Ministeri M; Cumbo S; Dalessandro V; Tamburino C
    Catheter Cardiovasc Interv; 2014 May; 83(6):907-12. PubMed ID: 23934631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score.
    Liu X; Zhang P; Zhang J; Zhang X; Yang S; Fu N
    Angiology; 2022 Jan; 73(1):33-41. PubMed ID: 34098771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
    Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
    Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): Study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for REduction of contraSt-induCed nephropathy followINg carDiac catheterization) trial.
    Liu Y; Chen JY; Huo Y; Ge JB; Xian Y; Duan CY; Chen SQ; Jiang W; Chen PY; Tan N;
    Am Heart J; 2016 Feb; 172():88-95. PubMed ID: 26856220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy.
    Wang J; Ai X; Li L; Gao Y; Sun N; Li C; Sun W
    Int Urol Nephrol; 2017 Nov; 49(11):2019-2026. PubMed ID: 28656510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
    Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial.
    Vasheghani-Farahani A; Sadigh G; Kassaian SE; Khatami SM; Fotouhi A; Razavi SA; Mansournia MA; Kazemisaeid A; Soleimani A; Pourhosseini HR; Alidoosti M; Hajizeinali AM; Hoseini K; Nematipour E
    J Nephrol; 2010; 23(2):216-23. PubMed ID: 20175053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.
    Li WH; Li DY; Qian WH; Liu JL; Xu TD; Zhu H; He HY
    Int Urol Nephrol; 2014 Apr; 46(4):781-6. PubMed ID: 24570327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention.
    Lin YS; Fang HY; Hussein H; Fang CY; Chen YL; Hsueh SK; Cheng CI; Yang CH; Chen CJ; Hang CL; Yip HK; Wu CJ
    EuroIntervention; 2014 Feb; 9(10):1173-80. PubMed ID: 24561734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Transient or Persistent Contrast-induced Nephropathy on Long-term Mortality After Elective Percutaneous Coronary Intervention.
    Abe M; Morimoto T; Nakagawa Y; Furukawa Y; Ono K; Kato T; Kadota K; Ando K; Ishii M; Masunaga N; Akao M; Kimura T
    Am J Cardiol; 2017 Dec; 120(12):2146-2153. PubMed ID: 29106836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-lipoic acid for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography: the ALIVE study - a prospective randomized trial.
    Jo SH; Kim SA; Kim HS; Han SJ; Park WJ; Choi YJ
    Cardiology; 2013; 126(3):159-66. PubMed ID: 23988855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
    Ma G; Li M; Teng W; He Z; Zhai X; Xia Z
    Medicine (Baltimore); 2022 Jan; 101(4):e28683. PubMed ID: 35089218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.